<PAGE>
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Dated January 11, 2000
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Translation of registrant's name into English)
2350 Cohen Street
-----------------
Saint Laurent, Quebec Canada H4R 2N6
------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ______ Form 40-F X (commenced in calendar
-----
year 1998)
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ____ No X
---
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): ______________
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Registrant)
Date: January 11, 2000 By: /s/ David Moszkowski
--------------- ---------------------
David Moszkowski
Senior Vice President and
Chief Financial Officer
<PAGE>
Exhibit 99.1
------------
NEWS RELEASE
PRESS RELEASE
For immediate release
PHOENIX INTERNATIONAL EXITS APPLICATIONS SOFTWARE BUSINESS
Montreal, Quebec - January 4th, 2000- Phoenix International Life Sciences Inc.
(NASDAQ: PHXI; TSE: PHX) today announced that it is exiting the commercial
applications software business. This action results in a reduction of about 25
people in the company's Information Technology workforce. A project team of
software specialists will be retained by Phoenix to service commercial clients
and internal systems.
"We are focusing our resources on what we do best. Applications software is not
our expertise. We remain committed to supporting our existing clients, but
Phoenix will no longer be involved in the future development and sale of
scientific software for the pharmaceutical industry," said Ian Lennox, CEO of
Phoenix International.
Phoenix International earlier announced the spin-off of its scientific software
division, Integraware. The intent of the new division was to independently
develop and market new software for the pharmaceutical industry. Market
conditions, Phoenix's need to gain access to the best applications software in
development and a new focus on shareholder value prompted the change in
strategic direction.
About Phoenix International
Phoenix International is one of the world's leading contract research
organizations. The company is a global leader in early stage pharmaceutical
development and has a growing presence in late stage pharmaceutical development.
Headquartered in Montreal, Quebec, Phoenix International employs over 2,000
people in 19 countries around the world. Phoenix International is on the world-
wide web at www.pils.com.
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.
<PAGE>
FOR MORE INFORMATION, PLEASE CONTACT:
MEDIA:
Richard Gareau
Director of Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033, extension 4638
E-mail: [email protected]
ANALYST CONTACT:
DAVID MOSZKOWSKI, C.A.
Senior Vice President and Chief Financial Officer
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033 Fax: (514) 335-8351
E-mail: [email protected]
<PAGE>
Exhibit 99.2
------------
NEWS RELEASE
PRESS RELEASE
For immediate release
PHOENIX INTERNATIONAL AND CURAGEN LAUNCH
----------------------------------------
TRANSGENIC RESEARCH PROGRAM
---------------------------
Montreal, Quebec -- January 10, 2000 - Phoenix International Life Sciences
(NASDAQ:PHXI; TSE:PHX), one of the world's leading contract research
organizations, today announced a transgenics science-based genomics research
program between its subsidiary DNX Transgenic Sciences of Cranbury, NJ and
CuraGen Corporation of New Haven, CT (NASDAQ: CRGN), an integrated genomics-
based drug discovery and development company.
Under the terms of the agreement, Phoenix International's DNX Transgenic
Sciences subsidiary will develop transgenic mice based upon a large number of
novel gene constructs provided by CuraGen. CuraGen will utilize these mice to
identify novel therapeutic protein drugs appropriate for further development.
"We are eager to begin working with a genomics focused company like CuraGen in
applying our high capacity transgenic capabilities to the drug development
process. Our new facilities in Cranbury are well suited for such high throughput
efforts," said Mark Swanson, Vice President-Transgenic Sciences. "With only
about 5,000 human genes characterized to date and an estimated 140,000 total
human genes soon to be identified, we are preparing for many more contracts of
this type."
"This agreement strengthens CuraGen's ability to deduce the therapeutic utility
of proprietary genes identified through CuraGen's suite of genomics technologies
and databases," stated Henri Lichenstein, Ph.D., Director of Drug Development
for CuraGen. "We look forward to utilizing the proven technology of transgenic
mice to accelerate CuraGen's internal protein therapeutic drug program."
Throughout the duration of the 3-year research agreement, CuraGen will fund the
development and characterization of transgenic mice from at least 45 unique gene
constructs. DNX and CuraGen will jointly genotype, select and characterize over
135 transgenic mouse lines in a flexible collaborative research program. The
transgenic research will take place in DNX's newly expanded research facilities
in Cranbury, NJ. The use of transgenic animal science has become an important
genomics tool to assist in the identification of novel protein therapeutics and
targets for pharmaceutical intervention.
CuraGen Corporation is advancing the discovery and development of pharmaceutical
and life science products through the systematic application of genomics.
CuraGen's fully integrated, Internet-based genomics technologies, services, and
information systems are designed to rapidly generate comprehensive information
about genes, human genetic variations, gene expression, biological pathways, and
potential products that affect these pathways. CuraGen's strategic collaborators
include Abgenix, Biogen, COR Therapeutics, Genentech, Glaxo Wellcome, Hoffmann-
La Roche, Pioneer Hi-Bred International, and Roche Vitamins. The Company employs
approximately
<PAGE>
300 people and is headquartered in New Haven, CT, with additional facilities in
Branford, CT and Alachua, FL. Additional Company information is available at
www.curagen.com.
- ---------------
DNX Transgenic Sciences, a wholly owned subsidiary of Phoenix International Life
Sciences, is a contract research organization providing transgenic animal
technologies to the worldwide biomedical research community. DNX integrates its
proprietary transgenic and gene targeting technologies, molecular biology,
animal science, and phenotypic analysis capabilities into customized research
programs for its clients to assist in the identification of new drug targets and
novel protein therapeutics and to provide specifically engineered animal models
for evaluation of therapeutic strategies.
Phoenix International is one of the world's leading contract research
organizations. The Company is a global leader in early stage pharmaceutical
development and has a growing presence in late stage pharmacetical development.
Headquarted in Montreal, Quebec, the Company employs over 2,000 people in 19
countries around the world. Phoenix International is on the worldwide web at
www.pils.com.
- ------------
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000 conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.
For more information, please contact:
Analysts:
David Moszkowski, C.A.
Senior Vice President and Chief Financial Officer
Phoenix International Life Sciences, Inc.
Tel: (514) 333-0033, Fax: (514) 335-8351
E-mail: [email protected]
-------------------------
Media:
Richard Gareau
Director of Communications
Phoenix International Life Sciences, Inc.
Tel: (514) 333-0033, Fax: (514) 335-8351
E-mail: [email protected]
---------------
Mark R. Vincent
Director, Corporate Communications
[email protected]
CuraGen Corporation
1-888-GENOMICS
www.curagen.com
- ---------------
